Artificial intelligence and machine learning are driving a paradigm shift in medicine,
promising data-driven, personalized solutions for managing diabetes and the excess …

The electronic health record (EHR) represents a rich source of patient information,
increasingly being leveraged for cardiovascular research. Although its primary use remains …

Introduction Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …

Abstract Elevated lipoprotein (a)(Lp (a)) is associated with premature atherosclerotic
cardiovascular disease. However, fewer than 0.5% of individuals undergo Lp (a) testing …

Artificial intelligence (AI) has the potential to transform every facet of cardiovascular practice
and research. The exponential rise in technology powered by AI is defining new frontiers in …

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce the risk of
cardiovascular (CV) complications in patients with type 2 diabetes (T2DM) and …

Advances in artificial intelligence (AI) and machine learning systems promise faster, more
efficient and more personalized care. While many of these models are built on the premise …

The advent of digital health and artificial intelligence (AI) has promised to revolutionize
clinical care, but real-world patient evaluation has yet to witness transformative changes. As …

Despite remarkable advances in the treatment of heart failure (HF), for some, this
progressive condition continues to worsen over time. Among the 6 million US adults with HF …

Background: SGLT2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1-RAs) reduce
major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus …